BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia

SIMPLE SUMMARY: Prognosis for acute myeloid leukemia (AML) patients is poor, particularly in TP53 mutated AML, secondary, relapsed, and refractory AML, and in patients unfit for intensive treatment, thus highlighting an unmet need for novel therapeutic approaches. Targeting the stem cell oncoprotein...

Descripción completa

Detalles Bibliográficos
Autores principales: Seipel, Katja, Kopp, Basil, Bacher, Ulrike, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867282/
https://www.ncbi.nlm.nih.gov/pubmed/33540760
http://dx.doi.org/10.3390/cancers13030581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867282/
https://www.ncbi.nlm.nih.gov/pubmed/33540760
http://dx.doi.org/10.3390/cancers13030581

Ejemplares similares